• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.

    5/12/25 10:44:44 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $CRL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Charles River Laboratories International, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    159864107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    159864107


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,871,306.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,285,012.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,285,012.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    159864107


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,871,306.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,285,012.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,285,012.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    159864107


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,871,306.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,285,012.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,285,012.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    159864107


    1Names of Reporting Persons

    Wellington Management Company LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,756,716.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,880,311.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,285,012.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.6 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Charles River Laboratories International, Inc.
    (b)Address of issuer's principal executive offices:

    251 Ballardvale Street, Wilmington MA 01887
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    159864107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.
    (b)Percent of class:

    8.38  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
     
    Wellington Group Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
     
    Wellington Management Company LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
    Get the next $CRL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRL

    DatePrice TargetRatingAnalyst
    7/9/2025$200.00Neutral → Buy
    Citigroup
    5/23/2025$182.00Neutral → Buy
    Redburn Atlantic
    5/14/2025$179.00Hold → Buy
    TD Cowen
    5/8/2025$170.00In-line → Outperform
    Evercore ISI
    3/21/2025$190.00 → $170.00Buy → Neutral
    Goldman
    3/4/2025$155.00 → $175.00Sell → Neutral
    Citigroup
    3/3/2025$188.00Sell → Neutral
    Redburn Atlantic
    1/22/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $CRL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, President and CEO Foster James C bought $1,002,436 worth of shares (6,075 units at $165.01), increasing direct ownership by 3% to 183,639 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    2/21/25 4:41:25 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Corporate Executive VP & COO Girshick Birgit bought $249,250 worth of shares (1,514 units at $164.63), increasing direct ownership by 3% to 55,058 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    2/21/25 4:38:37 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Girshick Birgit gifted 350 shares and bought $248,298 worth of shares (1,322 units at $187.82), increasing direct ownership by 53% to 44,449 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    11/21/23 5:07:01 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Charles River upgraded by Citigroup with a new price target

    Citigroup upgraded Charles River from Neutral to Buy and set a new price target of $200.00

    7/9/25 8:08:21 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River upgraded by Redburn Atlantic with a new price target

    Redburn Atlantic upgraded Charles River from Neutral to Buy and set a new price target of $182.00

    5/23/25 8:13:14 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River upgraded by TD Cowen with a new price target

    TD Cowen upgraded Charles River from Hold to Buy and set a new price target of $179.00

    5/14/25 8:48:54 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Charles River Laboratories Announces Second-Quarter 2025 Results

    – Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $3.12 – – Updates 2025 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter of 2025. For the quarter, revenue was $1,032.1 million, an increase of 0.6% from $1,026.1 million in the second quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.2%. Excluding this impact, revenue declined 0.5% on an organic basis. On a segment basis, an organic revenue decline in the Discovery and Safety Assessment (DSA) segment was partially offset by organic revenue growth

    8/6/25 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership

    Aim to Enhance Charles River Incubator and Accelerator Programs by adding crowdfunding features, aiding early-stage developers Charles River Laboratories International, Inc. (NYSE:CRL) and BioTech Social Inc. (BSI) today announced the exploration of a potential client-centric collaboration to enable Charles River Incubator (CIP) and Accelerator (CAP) Program participants to access the BioTech Funding Portal, an investment crowdfunding platform for life science companies. "We're thrilled to explore this collaboration that will open up an exciting new funding pathway to bridge innovation with the right audiences and investors. This dynamic approach would potentially streamline the deliver

    7/31/25 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

    Supporting fast-track production of therapeutic targeting ultra-rare neurodevelopmental disease Charles River Laboratories International, Inc. (NYSE:CRL) and Elly's Team, a parent-led foundation striving to find a cure for Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS), a rare genetic disorder, have announced a plasmid DNA contract development and manufacturing organization (CDMO) agreement. As part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program (CAP), Elly's Team accessed established gene therapy CDMO capabilities and advisory services to manufacture critical starting materials for a Phase I clinical trial. Thi

    7/22/25 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Corp Strategy & Develop Laplume Joseph W sold $60,016 worth of shares (400 units at $150.04), decreasing direct ownership by 2% to 24,916 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    8/8/25 4:18:55 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    New insider Mintz Mark claimed ownership of 6,350 shares (SEC Form 3)

    3 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    6/10/25 4:22:44 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP, Corp Strategy & Develop Laplume Joseph W gifted 385 shares, decreasing direct ownership by 1% to 25,316 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    6/9/25 4:21:38 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    SEC Filings

    View All

    SEC Form 144 filed by Charles River Laboratories International Inc.

    144 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    8/18/25 5:16:06 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Charles River Laboratories International Inc.

    10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    8/6/25 9:07:31 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    8/6/25 7:08:41 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Financials

    Live finance-specific insights

    View All

    Charles River Laboratories Announces Second-Quarter 2025 Results

    – Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $3.12 – – Updates 2025 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter of 2025. For the quarter, revenue was $1,032.1 million, an increase of 0.6% from $1,026.1 million in the second quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.2%. Excluding this impact, revenue declined 0.5% on an organic basis. On a segment basis, an organic revenue decline in the Discovery and Safety Assessment (DSA) segment was partially offset by organic revenue growth

    8/6/25 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

    Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 6th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe acce

    7/15/25 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Announces First-Quarter 2025 Results

    – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments. In the first quarter of 2025, the

    5/7/25 7:01:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Leadership Updates

    Live Leadership Updates

    View All

    Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

    – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company's Business – – Enters into Cooperation Agreement with Elliott Investment Management – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company's business focused on enhancing long-term value for shareholders. Charles River's Board o

    5/7/25 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery

    Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow

    7/24/24 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors

    Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership knowledge and sales and marketing expertise to Charles River's Board. As a member of the Board, Ms. Kemps-Polanco will serve on the Compensation and Strategic Planning and Capital Allocation Committees. "Reshema Kemp-Polanco's deep industry experience at two of the top-10, global pharmaceutical companies and demonstrated

    1/24/24 4:30:00 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Charles River Laboratories International Inc.

    SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    11/8/24 10:52:38 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Charles River Laboratories International Inc.

    SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    10/22/24 3:24:03 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by Charles River Laboratories International Inc. (Amendment)

    SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    2/13/24 5:01:02 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care